Illumina Inc. closed $13.90 short of its 52-week high ($144.02), which the company achieved on January 31st.

The stock's rise snapped a four-day losing streak.

GRAIL faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Click here to ...

On Thursday, Illumina Inc (ILMN) stock saw a modest uptick, ending the day at $132.27 which represents a slight increase of $6.12 or 4.85% from the prior close of $126.15. The stock opened at $128.04 ...

Illumina Inc (ILMN) stock saw a decline, ending the day at $128.82 which represents a decrease of $-1.28 or -0.98% from the prior close of $130.1. The stock opened at $130.49 and touched a low of $128 ...

The market bounced back Monday after a rough week last week. We are not out of the woods yet as a huge CPI report looms on ...

The Dutch competition watchdog is seeking beefed-up powers to probe more small deals that risk crushing competition in ...

Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomics, ...

The biotech sector is booming, fueled by rising healthcare demands, exciting advancements in technology, and increased FDA ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

Leerink Partners analyst Puneet Souda reiterated a Buy rating on Quanterix (QTRX – Research Report) today. The company’s shares ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Avantor (AVTR – Research Report) on September 22 and set a price target of ...